About US
Contact us
-
Lilly files lawsuit against home town spa for selling repackaged ZepboundTo what extent will health clinics go to keep selling in-demand weight loss drugs now that the FDA has outlawed cheaper compounded versions of the branded treatments? According to a lawsuit filed by2025/4/10
-
Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug XyremAhead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. Early this week, th2025/4/10
-
Sun Pharma snags appeals win over Incyte, clearing way for US launch of alopecia med LeqselviAfter a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with riv2025/4/8
-
Rhythm eyes label expansion after Imcivree helps patients with brain damage-related obesity lose weightWhile pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking to corner a subset of the market with its Imcivree. About 5,000 to 10,0002025/4/8
-
CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy developmentOn the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decis2025/4/3
-
Novo’s Wegovy, J&J’s Tremfya step up TV ad spending amid March Madness tournamentLast year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds totake the full-year titlefor the thi2025/4/3
-
RFK Jr. promotes measles vaccine as Texas outbreak continuesFollowing a second measles-related death in Texas, Robert F. Kennedy Jr., head of the federal Department of Health and Human Services, endorsed the measles, mumps, and rubella (MMR) vaccine in a leng2025/4/1
-
BMS prevails in antitrust lawsuit over its defense of multiple myeloma blockbuster PomalystA New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market exclusiv2025/4/1
-
After Starboard Value gets a seat on the board, another activist investor rallies for change at Kenvue: BloombergJohnson & Johnson’s consumer health spinout Kenvue is quickly amassing a track record of being a target for activist investors. Just after relenting in a brewing fight with Starboard Value, the c2025/3/27
-
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—againJiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor camrelizumab can enter the U.S. market. The FDA has once again issued a c2025/3/27